These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 8972122)

  • 21. [Drug sensitivity in Mycobacterium tuberculosis versus its viability, cytotoxicity, genotype, and the course of the process in patients with pulmonary tuberculosis].
    Manicheva OA; Lasunskaia EB; Zhuravlev VIu; Otten TF; Barnaulov AO; Mokrousov IV; Pavlova MV; Vishnevskiĭ BI; Narvskaia OV
    Probl Tuberk Bolezn Legk; 2008; (12):18-22. PubMed ID: 19230183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-resistant tuberculosis.
    Iseman MD; Madsen LA
    Clin Chest Med; 1989 Sep; 10(3):341-53. PubMed ID: 2505962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug-resistant pulmonary tuberculosis at the penitentiaries].
    Kononets AS
    Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
    Goldberg SV; Hanson D; Peloquin CA
    Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
    [No Abstract]   [Full Text] [Related]  

  • 26. Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?
    Wallis RS
    Am J Respir Crit Care Med; 2005 Jul; 172(1):4-5. PubMed ID: 15980108
    [No Abstract]   [Full Text] [Related]  

  • 27. [Methods in the modern chemotherapy of tuberculosis (a lecture)].
    Khomenko AG
    Probl Tuberk; 1988; (8):53-7. PubMed ID: 3143997
    [No Abstract]   [Full Text] [Related]  

  • 28. [The characteristics of the sensitivity of Mycobacterium tuberculosis to rifampicin and isoniazid through determination of mutations in the genes rpoB, katG, inhA, oxyR, and kasA by different molecular biological assays].
    Skotnikova OI; Galkina KIu; Nosova EIu; Krasnova MA; Moroz AM
    Probl Tuberk Bolezn Legk; 2005; (8):42-5. PubMed ID: 16209020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacoeconomic model of the use of rifabutin in new cases of pulmonary tuberculosis].
    Mednikov BL; Plaksin DI; Piiavskiĭ SA
    Probl Tuberk; 2002; (9):13-7. PubMed ID: 12524980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appropriateness of extending the intensive phase of treatment based on smear results.
    Enarson DA; Jindani A; Kuaban C; Lamothe F; Louissaint M; Ottmani SE; Ramarokoto H; Ridderhof JC; Urbanczik R
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):114-6. PubMed ID: 14974754
    [No Abstract]   [Full Text] [Related]  

  • 31. [Simultaneous resistance to rifampicin and isoniazid in patients with pulmonary tuberculosis].
    Ouedraogo M; Ouedraogo SM; Diagbouga S; Coulibaly G; Achi V; Domoua K; N'Dathz M; Yapi A
    Rev Mal Respir; 2000 Apr; 17(2):477-80. PubMed ID: 10859766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A new antitubercular agent: rifampicin].
    Favez G
    Schweiz Rundsch Med Prax; 1970 Feb; 59(8):296-7. PubMed ID: 4996719
    [No Abstract]   [Full Text] [Related]  

  • 33. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):10-5. PubMed ID: 9562106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Possibility of the intensification of tuberculosis chemotherapy and its limits].
    Naito M; Kanai K; Kondo E; Yamashita H; Matsui K
    Kekkaku; 1969 Nov; 44(11):377-93. PubMed ID: 4982567
    [No Abstract]   [Full Text] [Related]  

  • 35. [Outlook for using a short course of chemotherapy in tuberculosis].
    Anastasatu C; Corlan E
    Probl Tuberk; 1987; (10):31-4. PubMed ID: 3122200
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.
    Krüüner A; Pehme L; Ghebremichael S; Koivula T; Hoffner SE; Mikelsaar M
    Clin Infect Dis; 2002 Jul; 35(2):146-55. PubMed ID: 12087520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Approaches to combined therapy of pulmonary tuberculosis in adolescents excreting drug-resistant Mycobacterium tuberculosis].
    Firsova VA; Rusakova LI; Grigor'eva ZP; Ryzhova AP; Iatskova TV; Poluéktova FG
    Probl Tuberk; 2001; (1):28-30. PubMed ID: 11337776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.
    Sirgel FA; Botha FJ; Parkin DP; Van De Wal BW; Donald PR; Clark PK; Mitchison DA
    J Antimicrob Chemother; 1993 Dec; 32(6):867-75. PubMed ID: 8144427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000].
    Ratsirahonana O; Rasolofo Razanamparany V; Rasolonavalona T; Rakotonirina V; Rakotoarisaonina A; Rakotoherisoa A; Ralamboson M; Cauchoix B; Rakotondramarina D; Ramarokoto H
    Arch Inst Pasteur Madagascar; 2002; 68(1-2):44-7. PubMed ID: 12643091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice.
    Ji B; Truffot-Pernot C; Lacroix C; Raviglione MC; O'Brien RJ; Olliaro P; Roscigno G; Grosset J
    Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1541-6. PubMed ID: 8256897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.